vaccine safety

India should expand its domestic vaccine manufacturing and research to ensure greater control over vaccine safety and meet public health needs, according to a recent report from the Global Trade Research Initiative (GTRI). Released on Monday, the report advocates for bolstering India’s vaccine capabilities, emphasizing that locally produced vaccines could be better tailored to the specific health requirements of India’s population. GTRI also recommended that the Indian government establish a comprehensive system to track and investigate all adverse health events following vaccinations. Such a system would not only enhance transparency but also improve public trust in future vaccine rollouts by ensuring a clear record of potential health impacts. The report gained added significance with the recent release of The Pfizer Papers: Crimes Against Humanity, a publication that has sparked international dialogue regarding vaccine safety and ethical transparency in the pharmaceutical industry. GTRI noted that this development has brought renewed attention to the importance of ethical practices and prioritizing public health over profit. Ajay Srivastava, GTRI’s founder, highlighted the potential of The Pfizer Papers insights to guide future global health strategies. “As the world prepares for future pandemics, the insights from The Pfizer Papers provide a foundation for building safer, more effective, and more trustworthy vaccination strategies,” Srivastava stated. He emphasized that the lessons learned can ensure that public health remains at the forefront of global vaccine responses, reinforcing the need for countries like India to prioritize self-sufficiency in vaccine development and safety standards. Source: Business Standard Photo Credit: Business Standard